Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.

导出 LinkOut

翻译打印收藏纠错

作者： Hiroki,Ikeda ^[1] ; Tsunamasa,Watanabe ^[1] ; Hirohito,Shimizu ^[2] ; Tetsuya,Hiraishi ^[1] ; Rena,Kaneko ^[3] ; Toshiyuki,Baba ^[4] ; Hideaki,Takahashi ^[5] ; Kotaro,Matsunaga ^[6] ; Nobuyuki,Matsumoto ^[1] ; Hiroshi,Yasuda ^[1] ; Chiaki,Okuse ^[1] ; Shogo,Iwabuchi ^[1] ; Michihiro,Suzuki ^[3] ; Fumio,Itoh ^[2]

作者单位： Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan. ^[1] Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan. ^[2] Division of Gastroenterology and Hepatology, Kawasaki Municipal Tama Hospital, Kawasaki, Japan. ^[3] Department of Gastroenterology, Japan Labour Health and Welfare Organization Kanto Rosai Hospital, Kawasaki, Japan. ^[4] Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. ^[5] Division of Gastroenterology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan. ^[6]

关键词 P32 deletion hepatitis C virus ledipasvir nonstructural protein 5A inhibitor retreatment ribavirin sofosbuvir

DOI 10.1111/hepr.13074

PMID 29504692

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交